NDAORALTABLET
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Mechanism of Action
Prucalopride, a selective serotonin type 4 (5-HT 4 ) receptor agonist, is a gastrointestinal (GI) prokinetic agent that stimulates colonic peristalsis (high-amplitude propagating contractions [HAPCs]), which increases bowel motility. Prucalopride was devoid of effects mediated via 5-HT 2A , 5-HT 2B…
Indications (1)
Clinical Trials (5)
A Study of Prucalopride in Breastfeeding Women With Constipation
Started Mar 2022
12 enrolled
Chronic Idiopathic Constipation (CIC)
A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy
Started Jan 2022
100 enrolled
ConstipationPregnancy
A Study of Prucalopride For Functional Constipation in Children and Teenagers
Started Jul 2021
175 enrolled
Constipation
Post-Marketing Study of Prucalopride Safety In Pregnancy
Started May 2021
127 enrolled
Chronic Idiopathic Constipation (CIC)
Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation
Started Oct 2014
280 enrolled
Constipation